Revenue Potential: Apitegromab has a total revenue potential of greater than $1 billion. Scholar Rock Holding Corp ...

Scholar Rock Holding ( (SRRK) ) has released its Q3 earnings. Here is a breakdown of the information Scholar Rock Holding presented to its ...

H.C. Wainwright raised the firm’s price target on Scholar Rock (SRRK) to $40 from $35 and keeps a Buy rating on the shares. Scholar Rock ...

November 12, 2024--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing ...

Good morning and welcome to Scholar Rock's Third Quarter 2024 Financial Results and Business Update Call. All participants will be in listen-only mode. After the company’s prepared remarks all ...

Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) has been given a consensus rating of “Buy” by the seven brokerages ...

Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) by 28.2% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 748,489 shares ...

Data support that Scholar Rock’s unique approach to selective myostatin inhibition could improve body composition in people living with obesity and on an existing background treatment - Scholar ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases ...